Lilly starts Phase III trials of Alzheimer's antibody
This article was originally published in Scrip
Executive Summary
Lilly has started two separate, but identical, Phase III trials to test solanezumab, an anti-amyloid beta monoclonal antibody, against mild to moderate Alzheimer's disease.